To the Editor:Multiple myeloma(MM)is a plasma cell disease that remains incurable.Novel anti-MMtherapies are currently in clinical research,including CAR-T therapy,bispecific antibodies,and XPO1 inhibitors1.XPO1 is a ...To the Editor:Multiple myeloma(MM)is a plasma cell disease that remains incurable.Novel anti-MMtherapies are currently in clinical research,including CAR-T therapy,bispecific antibodies,and XPO1 inhibitors1.XPO1 is a nuclear export protein that helps leucine-rich proteins transport from the nucleus to the cytoplasm.XPO1 is highly expressed in patients with MM and XPO1 overexpression is associated with short PFS and OS^(2).These observations suggest that XPO1 has considerable value as a therapeutic target for patients with MM.展开更多
Multi-drug delivery focuses on different signaling pathways in cancer cells and has synergistic antiproliferative effects.In this manuscript,we developed folic acid(FA)-conjugated polymeric multi-drug nanoparticles(FA...Multi-drug delivery focuses on different signaling pathways in cancer cells and has synergistic antiproliferative effects.In this manuscript,we developed folic acid(FA)-conjugated polymeric multi-drug nanoparticles(FA-PMDNPs)consisting of poly-L-lysine(PLL)and poly glutamic-conjugated PTX/GEM(PGA-PTX and PGA-GEM)for FA receptor-targeted synergistic breast cancer therapy.The carboxyl-rich structure of PGA provided plenty reaction sites and negative charge for drug loading.Transmission electron microscopy(TEM)results showed that FA-PMDNPs had uniform particle size and spherical morphology.The hemolysis study proved that FA-PMDNPs had good biocompatibility.In vitro cell viability and in vivo studies showed that FA-PMDNPs more effectively inhibited the proliferation of FA receptor(FR)-overexpressing breast cancer cells(4T1)than the pure drugs.Consequently,these results demonstrated that FA-PMDNPs could be effectively targeted at cancer cells compared with free drugs,indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.展开更多
基金supported by grants from the National Natural Science Foundation of China(Nos.82070223 and 82370205)the Social Development Project of Jiangsu Science and Technology Plan(No.BE2022810,China).
文摘To the Editor:Multiple myeloma(MM)is a plasma cell disease that remains incurable.Novel anti-MMtherapies are currently in clinical research,including CAR-T therapy,bispecific antibodies,and XPO1 inhibitors1.XPO1 is a nuclear export protein that helps leucine-rich proteins transport from the nucleus to the cytoplasm.XPO1 is highly expressed in patients with MM and XPO1 overexpression is associated with short PFS and OS^(2).These observations suggest that XPO1 has considerable value as a therapeutic target for patients with MM.
基金National Natural Science Foundation of China(Grant No.21877061)Natural Science Foundation of Jiangsu Province(Grant No.BK20171448)National and Local Joint Engineering Research Center of Biomedical Functional Materials。
文摘Multi-drug delivery focuses on different signaling pathways in cancer cells and has synergistic antiproliferative effects.In this manuscript,we developed folic acid(FA)-conjugated polymeric multi-drug nanoparticles(FA-PMDNPs)consisting of poly-L-lysine(PLL)and poly glutamic-conjugated PTX/GEM(PGA-PTX and PGA-GEM)for FA receptor-targeted synergistic breast cancer therapy.The carboxyl-rich structure of PGA provided plenty reaction sites and negative charge for drug loading.Transmission electron microscopy(TEM)results showed that FA-PMDNPs had uniform particle size and spherical morphology.The hemolysis study proved that FA-PMDNPs had good biocompatibility.In vitro cell viability and in vivo studies showed that FA-PMDNPs more effectively inhibited the proliferation of FA receptor(FR)-overexpressing breast cancer cells(4T1)than the pure drugs.Consequently,these results demonstrated that FA-PMDNPs could be effectively targeted at cancer cells compared with free drugs,indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.
